GLP-1s and Gout: What the Uric Acid Research Actually Shows

GLP-1 medications appear to lower uric acid modestly, and most of that effect seems to come from the weight people lose on them. That is a real, measured finding from trial data. What has not been shown is that taking a GLP-1 drug prevents gout attacks. The studies that look at actual flares are observational, several exist only as conference abstracts, and they don't agree with each other.

So the honest answer for someone with gout or high uric acid is: weight loss is good for gout, GLP-1s are effective at producing weight loss, and the direct evidence that the drug itself protects your joints is still early.

Why uric acid and weight are linked

Gout happens when uric acid builds up enough to form crystals in a joint, often the big toe. The CDC lists obesity as a factor that can raise uric acid, alongside alcohol (beer and liquor in particular), sugary drinks, red and organ meats, certain seafood, diuretics, and conditions like insulin resistance, diabetes, high blood pressure, and reduced kidney function. Many people who are candidates for a GLP-1 drug check several of those boxes at once.

Because of that overlap, the 2020 American College of Rheumatology gout guideline conditionally recommends a weight-loss program for people with gout who are overweight or obese. It does not name a specific method. That guideline predates the current generation of obesity drugs, so it says nothing about GLP-1s one way or the other.

What the trial data show about uric acid

The strongest evidence comes from a post hoc analysis of SURMOUNT-1, the 72-week randomized, placebo-controlled trial of tirzepatide in 2,539 adults with obesity or overweight. The analysis, published in the Annals of the Rheumatic Diseases, reported these average changes in serum uric acid at week 72:

Two details matter for reading this correctly. First, mediation analysis estimated that weight reduction accounted for about 72.7% of the urate drop, so the drug seems to work mainly through weight loss rather than through a separate kidney or metabolic pathway. Second, uric acid was not a planned primary outcome of the trial, and participants were not selected because they had gout. That makes the result solid for "tirzepatide lowers urate on average" and silent on "tirzepatide prevents gout flares."

Semaglutide data

For semaglutide, the available urate data are smaller and observational. A retrospective Spanish study of 236 people with type 2 diabetes taking oral semaglutide, published in Seminars in Arthritis and Rheumatism in 2025, reported modest urate reductions, mainly in people who started with levels at or above 6 mg/dL. It had no control group, so it can't separate the drug's effect from other changes in care.

A Mass General Brigham records review presented at ACR Convergence 2025 looked specifically at people with gout and high uric acid who started semaglutide or tirzepatide. Each kilogram lost was associated with about a 0.13 mg/dL lower urate, and people who lost more than 10% of body weight had larger drops than those who lost under 5%. This study included only 22 patients, so it is a signal, not a conclusion.

What observational studies show about gout risk

Here the picture gets messier. Database studies compare people who happened to receive a GLP-1 with people who received something else, and the answer depends heavily on what "something else" is.

A few ways to read that table without overreaching:

• The comparator drives the result. Against DPP-4 inhibitors, which cause little weight loss, GLP-1 users had less gout. Against people not on a GLP-1 at all, GLP-1 users had slightly more. People who get prescribed a GLP-1 often have heavier, more advanced metabolic disease, and matching can't fully correct for that.
• SGLT2 inhibitors look better for urate specifically. In both the 2020 Annals study and a 2024 analysis of people with existing gout, SGLT2 drugs beat GLP-1 drugs on gout outcomes.
• Conference abstracts are preliminary. The TriNetX authors themselves described their findings as observational and needing confirmation. The AAOS 2026 abstract reporting higher risk has the same limits in the other direction.

The fair summary: no consistent evidence that GLP-1s cause gout, no proof that they prevent it, and some evidence that another diabetes drug class does more for uric acid.

Can starting a GLP-1 trigger a flare?

This hasn't been studied directly for GLP-1 drugs, so there is no data on flare rates in the first months of treatment. Two general principles are worth knowing, though.

First, a review in the American Journal of Lifestyle Medicine notes that abrupt weight loss and starvation-type eating can produce ketosis, which raises serum uric acid by increasing reabsorption in the kidney. The same review favors gradual weight loss for people with gout. Someone eating very little because of strong appetite suppression could, in theory, land in that territory.

Second, dehydration concentrates uric acid. GLP-1 drugs commonly cause nausea, vomiting, and diarrhea, and the Wegovy prescribing information warns about acute kidney injury from volume depletion, mostly in people who had GI side effects. Reduced kidney function also reduces uric acid clearance. That combination is a reason to take hydration seriously during dose increases.

If you already have gout

A GLP-1 is not a gout medication, and none is FDA-approved for gout or hyperuricemia. If you take allopurinol, febuxostat, or another urate-lowering drug, the ACR guideline's strong recommendation is to adjust it to reach a target urate below 6 mg/dL. Starting a GLP-1 doesn't change that target, and stopping your gout medication because you're losing weight is a decision for your prescriber, guided by repeat urate levels.

Things that are worth raising with whoever manages your gout:

• Whether to recheck serum urate a few months into GLP-1 treatment, since weight loss may lower it.
• What to do if you have a flare while your appetite is suppressed. Some flare medications, such as NSAIDs and colchicine, can upset the stomach, and a GLP-1 may already be doing that.
• Whether you take a diuretic, which can raise uric acid, and whether that still fits as your blood pressure changes with weight loss.
• If you have type 2 diabetes, whether an SGLT2 inhibitor alongside or instead of other therapy makes sense given the gout data. Our piece on combining SGLT2 and GLP-1 drugs covers how prescribers think about that pairing.

What to do next

1. Get a baseline urate. If you have gout or a history of high uric acid, ask for a serum urate with your pre-treatment labs so later changes mean something.
2. Tell both prescribers. Your GLP-1 prescriber should know you have gout and what you take for it. Your gout doctor or primary care clinician should know you started a GLP-1.
3. Keep your gout plan. Continue urate-lowering therapy as prescribed. Don't stop or cut it based on weight loss alone.
4. Hydrate through dose changes. Plan fluids around injection days and the first week after each increase, when GI side effects tend to be worse.
5. Avoid crash-level eating. If appetite suppression has you eating very little, tell your prescriber. Going slower can be better for both your joints and your muscle.
6. Watch the usual triggers. Beer, liquor, and sugary drinks still matter. A GLP-1 doesn't cancel them out.

For a broader look at where the off-label and secondary research on these drugs stands, see GLP-1s beyond weight loss.